{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:15:49Z","timestamp":1791281749482,"version":"4.1.0"},"reference-count":24,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:p>OBJECTIVE. Our goal was to evaluate the long-term safety and efficacy of recombinant human \u03b1-l-iduronidase (laronidase) in patients with mucopolysaccharidosis I.<\/jats:p><jats:p>PATIENTS AND METHODS. All 45 patients who completed a 26-week, double-blind, placebo-controlled trial of laronidase were enrolled in a 3.5-year open-label extension study. Mean patient age at baseline was 16 (range: 6\u201343) years. All patients had attenuated disease (84% Hurler-Scheie, 16% Scheie phenotypes). Clinical, biochemical, and health outcomes measures were evaluated through the extension phase. Changes are presented as the mean \u00b1 SEM.<\/jats:p><jats:p>RESULTS. All 40 patients (89%) who completed the trial received at least 80% of scheduled infusions. As shown in earlier trials, urinary glycosaminoglycan levels decreased within the first 12 weeks and liver volume decreased within the first year. Percent predicted forced vital capacity remained stable, with a linear slope of \u22120.78 percentage points per year. The 6-minute walk distance increased 31.7 \u00b1 10.2 m in the first 2 years, with a final gain of 17.1 \u00b1 16.8 m. Improvements in the apnea\/hypopnea index (decrease of 7.6 \u00b1 4.5 events per hour among the patients with significant baseline sleep apnea) and shoulder flexion (increase of 17.4\u00b0 \u00b1 3.6\u00b0) were most rapid during the first 2 years. Improvements in the Child Health Assessment Questionnaire\/Health Assessment Questionnaire disability index (decrease of 0.31 \u00b1 0.11, signifying a clinically meaningful improvement in activities of daily living) were gradual and sustained over the treatment period. Laronidase infusions were generally well tolerated except in 1 patient who experienced an anaphylactic reaction. Infusion-associated reactions, which occurred in 53% of the patients, were mostly mild, easily managed, and decreased markedly after 6 months. One patient died as a result of an upper respiratory infection unrelated to treatment. Antibodies to laronidase developed in 93% of the patients; 29% of the patients were seronegative at their last assessment.<\/jats:p><jats:p>CONCLUSIONS. This trial demonstrates the long-term clinical benefit and safety of laronidase in attenuated patients with mucopolysaccharidosis I and highlights the magnitude and chronology of treatment effects. Prompt diagnosis and early treatment will maximize treatment outcomes.<\/jats:p>","DOI":"10.1542\/peds.2007-3847","type":"journal-article","created":{"date-parts":[[2008,12,29]],"date-time":"2008-12-29T15:58:03Z","timestamp":1230566283000},"page":"229-240","source":"Crossref","is-referenced-by-count":297,"title":["Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I"],"prefix":"10.1542","volume":"123","author":[{"given":"Lorne A.","family":"Clarke","sequence":"first","affiliation":[{"name":"Department of Medical Genetics, University of British Columbia and Children's and Women's Health Center of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Edmond","family":"Wraith","sequence":"additional","affiliation":[{"name":"Willink Biochemical Genetics Unit, Royal Manchester Children's Hospital, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children's Hospital, University of Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin H.","family":"Kolodny","sequence":"additional","affiliation":[{"name":"Departments of Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Pastores","sequence":"additional","affiliation":[{"name":"Departments of Neurology"},{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Muenzer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Rapoport","sequence":"additional","affiliation":[{"name":"Medicine, New York University School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth I.","family":"Berger","sequence":"additional","affiliation":[{"name":"Medicine, New York University School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Sidman","sequence":"additional","affiliation":[{"name":"Genzyme Corporation, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil D.","family":"Kakkis","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc, Novato, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Cox","sequence":"additional","affiliation":[{"name":"Genzyme Corporation, Cambridge, Massachusetts"},{"name":"Division of Genetics, Children's Hospital Boston, Boston, Massachusetts"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2009,1,1]]},"reference":[{"key":"2021120905114681300_R1","unstructured":"Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver C, Beaudet A, Sly W, Valle D, Childs B, Kinzler K, et al., eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw Hill; 2001:3421\u20133452"},{"key":"2021120905114681300_R2","doi-asserted-by":"crossref","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA.\u20081999;281(3):249\u2013254","DOI":"10.1001\/jama.281.3.249"},{"key":"2021120905114681300_R3","doi-asserted-by":"crossref","unstructured":"Terlato NJ, Cox GF. Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet Med.\u20082003;5(4):286\u2013294","DOI":"10.1097\/01.GIM.0000078027.83236.49"},{"key":"2021120905114681300_R4","doi-asserted-by":"crossref","unstructured":"Pastores G, Arn P, Beck M, et al. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol Genet Metab.\u20082007;91(1):37\u201347","DOI":"10.1016\/j.ymgme.2007.01.011"},{"key":"2021120905114681300_R5","doi-asserted-by":"crossref","unstructured":"Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med.\u20082001;344(3):182\u2013188","DOI":"10.1056\/NEJM200101183440304"},{"key":"2021120905114681300_R6","doi-asserted-by":"crossref","unstructured":"Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab.\u20082007;90(2):171\u2013180","DOI":"10.1016\/j.ymgme.2006.08.007"},{"key":"2021120905114681300_R7","doi-asserted-by":"crossref","unstructured":"Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha- L-iduronidase (laronidase). Pediatrics.\u20082007;120(1). Available at: www.pediatrics.org\/cgi\/content\/full\/120\/1\/e37","DOI":"10.1542\/peds.2006-2156"},{"key":"2021120905114681300_R8","doi-asserted-by":"crossref","unstructured":"Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase). J Pediatr.\u20082004;144(5):581\u2013588","DOI":"10.1016\/j.jpeds.2004.01.046"},{"key":"2021120905114681300_R9","unstructured":"Armitage P, Berry G. Statistical Methods in Medical Research. London, Great Britain: Chapman and Hall; 1987"},{"key":"2021120905114681300_R10","doi-asserted-by":"crossref","unstructured":"Khuri A, Mathew T, Sinha B. Statistical Tests for Mixed Linear Models. New York, NY: John Wiley & Sons; 1998","DOI":"10.1002\/9781118164860"},{"key":"2021120905114681300_R11","doi-asserted-by":"crossref","unstructured":"Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med.\u20081998;158(5 pt 1):1384\u20131387","DOI":"10.1164\/ajrccm.158.5.9710086"},{"key":"2021120905114681300_R12","doi-asserted-by":"crossref","unstructured":"Cocchiarella L, Andersson G. Chapter 16: The upper extremities. In: Guides to the Evaluation of Permanent Impairment. 5th ed. New York, NY: AMA Press; 2001:433\u2013521","DOI":"10.1001\/978-1-57947-085-2"},{"key":"2021120905114681300_R13","doi-asserted-by":"crossref","unstructured":"Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis.\u20081991;144(5):1202\u20132318","DOI":"10.1164\/ajrccm\/144.5.1202"},{"key":"2021120905114681300_R14","doi-asserted-by":"crossref","unstructured":"Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med.\u20081997;155(4):1278\u20131282","DOI":"10.1164\/ajrccm.155.4.9105067"},{"key":"2021120905114681300_R15","doi-asserted-by":"crossref","unstructured":"Ferris FL, 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol.\u20081982;94(1):91\u201396","DOI":"10.1016\/0002-9394(82)90197-0"},{"key":"2021120905114681300_R16","doi-asserted-by":"crossref","unstructured":"Reeves BC, Wood JM, Hill AR. Reliability of high- and low-contrast letter charts. Ophthalmic Physiol Opt.\u20081993;13(1):17\u201326","DOI":"10.1111\/j.1475-1313.1993.tb00421.x"},{"key":"2021120905114681300_R17","doi-asserted-by":"crossref","unstructured":"Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE, Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum.\u20082000;43(7):1478\u20131487","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M"},{"key":"2021120905114681300_R18","doi-asserted-by":"crossref","unstructured":"Anbu AT, Mercer J, Wraith JE. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I. J Inherit Metab Dis.\u20082006;29(1):230\u2013231","DOI":"10.1007\/s10545-006-0237-8"},{"key":"2021120905114681300_R19","doi-asserted-by":"crossref","unstructured":"Soutar RL, Mercer J, Wraith JE. Impact of 144 weeks of laronidase therapy on body functions, endurance and general well-being in a Hurler-Scheie patient. J Inherit Metab Dis.\u20082006;29:590","DOI":"10.1007\/s10545-006-0329-5"},{"key":"2021120905114681300_R20","doi-asserted-by":"crossref","unstructured":"Tokic V, Barisic I, Huzjak N, Petkovic G, Fumic K, Paschke E. Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I. Eur J Pediatr.\u20082007;166(7):727\u2013732","DOI":"10.1007\/s00431-006-0316-8"},{"key":"2021120905114681300_R21","doi-asserted-by":"crossref","unstructured":"Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, et al. Gaucher disease: clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore).\u20081992;71:337\u2013353","DOI":"10.1097\/00005792-199211000-00002"},{"key":"2021120905114681300_R22","doi-asserted-by":"crossref","unstructured":"Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E. Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet.\u20081989;12(2):349\u2013352","DOI":"10.1016\/S0140-6736(89)90536-9"},{"key":"2021120905114681300_R23","doi-asserted-by":"crossref","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology.\u20081983;33(11):1444\u20131452","DOI":"10.1212\/WNL.33.11.1444"},{"key":"2021120905114681300_R24","unstructured":"van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol.\u20081993;20(3):579\u2013581"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/123\/1\/229\/1124890\/zpe00109000229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/123\/1\/229\/1124890\/zpe00109000229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T05:58:53Z","timestamp":1684821533000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/123\/1\/229\/71973\/Long-term-Efficacy-and-Safety-of-Laronidase-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,1,1]]},"published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-3847","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}